Lonza Group Ltd is expanding its Cell Therapy business with the construction of a new facility in Singapore. This new facility will broaden the global presence and consolidate Lonza's leading position in the area of Cell Therapy production. The new facility will be located adjacent to Lonza's large-scale mammalian manufacturing facility at Tuas Biomedical Park. The total investment for the first phase will be approximately CHF 30 million.

Cellular-based therapeutics promise to address many unmet medical needs across many disease categories. Lonza, with twelve existing cGMP-certified cell therapy manufacturing suites in the USA and Europe, is uniquely positioned to provide full custom manufacturing support for this type of therapies worldwide.

“This new Cell Therapy manufacturing facility is a next step in fulfilling our strategy to expand our capacity globally and our presence in Asia. Cell Therapy is expected to be one of the most important innovation drivers of modern medicine and this new facility reinforces Lonza’s leading position as a custom manufacturer of cellular therapeutics”, comments Stefan Borgas, CEO of Lonza. “The facility will operate with cutting-edge technologies and a skilled labor force, allowing it to readily meet the needs of a broad range of customers and address the growing global demand for Cell Therapies. This expansion in Singapore further fortifies the strategic relationship Lonza has with the Singapore government, which has been developed through the successful build-up of our large-scale mammalian facility.”